Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.
Matthew CapehornNino HallénJames Baker-KnightDivina GlahBarnaby HuntPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
Once-weekly semaglutide 1 mg was projected to be a cost-effective treatment option from a healthcare payer perspective compared with empagliflozin 25 mg for the treatment of patients with type 2 diabetes in the UK setting.
Keyphrases